Brief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
18/08/2026 13:04
BRIEF-Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation Entera Bio Ltd 5DT.F:
ENTERA APPOINTS GLOBAL PHARMACEUTICAL LEADER RICCARDO PAOLO CAMISASCA, M.D., AS CHIEF MEDICAL OFFICER AHEAD OF PLANNED EB613 PHASE 3 INITIATION
Source text: ID:nGNX8B2hBm
Further company coverage: 5DT.F
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement